These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38338814)

  • 1. Attention Deficit Hyperactivity Disorder (ADHD) and Polyphenols: A Systematic Review.
    Turiaco F; Cullotta C; Mannino F; Bruno A; Squadrito F; Pallio G; Irrera N
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Gillies D; Sinn JKh; Lad SS; Leach MJ; Ross MJ
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007986. PubMed ID: 22786509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
    Eaton C; Yong K; Walter V; Mbizvo GK; Rhodes S; Chin RF
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013136. PubMed ID: 35844168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial.
    Verlaet AA; Ceulemans B; Verhelst H; Van West D; De Bruyne T; Pieters L; Savelkoul HF; Hermans N
    Trials; 2017 Mar; 18(1):145. PubMed ID: 28351412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stress as a mediator of brain alterations in attention-deficit hyperactivity disorder: A systematic review.
    Koppelmaa K; Yde Ohki CM; Walter NM; Walitza S; Grünblatt E
    Compr Psychiatry; 2024 Apr; 130():152454. PubMed ID: 38281339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.
    Zwi M; Jones H; Thorgaard C; York A; Dennis JA
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD003018. PubMed ID: 22161373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Otasowie J; Castells X; Ehimare UP; Smith CH
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006997. PubMed ID: 25238582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
    Castells X; Blanco-Silvente L; Cunill R
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Gillies D; Leach MJ; Perez Algorta G
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research.
    Richardson M; Moore DA; Gwernan-Jones R; Thompson-Coon J; Ukoumunne O; Rogers M; Whear R; Newlove-Delgado TV; Logan S; Morris C; Taylor E; Cooper P; Stein K; Garside R; Ford TJ
    Health Technol Assess; 2015 Jun; 19(45):1-470. PubMed ID: 26129788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol.
    He S; Wang M; Si J; Zhang T; Cui H; Gao X
    BMJ Open; 2018 Feb; 8(2):e020434. PubMed ID: 29463592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention-deficit/ hyperactivity disorder mobile apps: A systematic review.
    Păsărelu CR; Andersson G; Dobrean A
    Int J Med Inform; 2020 Jun; 138():104133. PubMed ID: 32283479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Suicide Risk of Children and Adolescents With Attention Deficit and Hyperactivity Disorder-A Systematic Review.
    Garas P; Balazs J
    Front Psychiatry; 2020; 11():557909. PubMed ID: 33408650
    [No Abstract]   [Full Text] [Related]  

  • 17. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder.
    Coghill DR; Banaschewski T; Soutullo C; Cottingham MG; Zuddas A
    Eur Child Adolesc Psychiatry; 2017 Nov; 26(11):1283-1307. PubMed ID: 28429134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.